FDA Rejects Sanofi-Aventis Drug Application

Law360, New York (September 1, 2006, 12:00 AM EDT) -- Pharmaceutical giant Sanofi-Aventis suffered a blow this week when the U.S. Food and Drug Administration refused to approve its cardiovascular drug, Multaq.

The FDA issues letters when company applications don’t adequately demonstrate a drug’s safety or efficacy. Sanofi-Aventis didn't say why Multaq, which the company hopes will be a blockbuster, was rejected.

Sanofi-Aventis, the world’s third-largest pharmaceutical company, said it would refile an application for the drug at the beginning of next year. The company is hoping to bolster its case with clinical data from an...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.